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Rev Activity Determines Sensitivity
of HIV-1-Infected Primary T Cells to CTL Killing
T cells that are necessary for the maintenance of anti-
HIV-1 CTLs are rapidly lost following infection (for review
see Walker [2001]). This could lead to a decline in CTLs
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and Kathleen L. Collins1,2,* or to defects in their maturation (Appay et al., 2000;
Champagne et al., 2001; Walker, 2001). Direct infection1Department of Internal Medicine
2 Department of Microbiology and Immunology of CTLs by HIV-1 has been reported and could contrib-
ute to their depletion (Kitchen et al., 1998; McBreen et1150 West Medical Center Drive
The University of Michigan al., 2001). In addition, the low density of HIV-1 epitopes
(peptides presented in association with MHC-I) limitsAnn Arbor, Michigan 48109
3 AIDS Research Center and Infectious Disease Unit CTL recognition and killing (Collins and Baltimore, 1999;
Collins et al., 1998; Tsomides et al., 1994). Finally, thereMassachusetts General Hospital
Charlestown, Massachusetts 02114 is evidence that CTLs are directly killed by the actions
of viral gene products (Herbein et al., 1998; Xu et al.,
1997). Given the fact that untreated HIV is virtually al-
ways lethal, it is likely that multiple different mechanismsSummary
combine to promote HIV immune evasion.
To directly determine whether HIV-1 factors could in-The HIV Nef protein is thought to promote HIV immune
evasion by downmodulating MHC-I and protecting in- fluence CTL recognition, a system was developed in which
infected cells were identified by the expression of a markerfected cells from CTL killing. In addition, we demon-
strated that Rev, an HIV regulatory protein needed for gene, placental alkaline phosphatase (PLAP). This sys-
tem was used to monitor anti-HIV-1 CTL lysis of primaryexpression of the HIV late genes, can influence CTL
killing. When Rev activity level was reduced by virtue T lymphocytes infected with HIV-1, and it was found
that HIV-1 encodes multiple factors that influence sus-of amino acid alterations in the Rev protein sequence,
infected cells were more resistant to anti-Gag and ceptibility to CTLs (Collins and Baltimore, 1999; Collins
et al., 1998). One of these factors, called Nef, promotesanti-Env CTL killing. A screen of primary viral isolates
revealed that viruses derived from asymptomatic, in- immune evasion by reducing the cell surface expression
of MHC-I necessary for CTL recognition. An importantfected people had lower Rev activity, lower Gag levels,
and greater resistance to anti-Gag CTL killing. Thus, role for Nef-mediated MHC-I downmodulation was re-
cently confirmed using a CTL coculture assay systemrev alleles with low activity may have a selective ad-
vantage in infected people with effective immune re- (Yang et al., 2002) and an in vivo simian model system
(Munch et al., 2001).sponses.
Here, we used the flow cytometric CTL assay system
described above to demonstrate that the activity levelIntroduction
of another factor, called Rev, can influence CTL killing.
Rev functions by promoting the transport of unsplicedCytotoxic T lymphocytes (CTLs) are important for pre-
venting and controlling viral infections (Cooper et al., and partially spliced transcripts from the nucleus to the
cytoplasm so that the late gene products (Gag, Pol, Env,1999; Goulder et al., 1997; Lechner et al., 2000; Maini
et al., 1999; Rickinson and Moss, 1997; Riddell et al., Vpu, Vpr, and Vif) can be synthesized. We demonstrated
that an attenuating mutation in the rev gene, which re-1992; Schmitz et al., 1999 ; Yap et al., 1978; Zinkernagel,
1996). CTLs identify infected cells by detecting foreign duces Gag expression 2- to 3-fold, is enough to limit
anti-Gag CTL killing. Although this mutation was intro-peptides presented on the cell surface in the cleft of
MHC class I molecules (MHC-I). When a foreign peptide duced artificially, the amino acid change at that position
(L60F) is found naturally in a number of primary isolatesis recognized, CTLs secrete perforins and granzymes,
leading to lysis of the infected cell. In HIV individuals, (Carr et al., 2001a, 2001b; Novitsky et al., 1999). More-
over, several natural rev alleles from asymptomatic indi-anti-HIV CTLs are abundant, and they initially control
the virus. Eventually, however, the virus overcomes the viduals behaved similarly. The data presented here sug-
gest that low Rev activity limits CTL killing by reducingimmune system, and the acquired immunodeficiency
syndrome (AIDS) develops. It is likely that HIV disease Gag but not Nef levels. In this manner, HIV-1-infected
cells may effectively evade the most abundant anti-progression and the problems encountered in vaccine
development are complicated by the ability of HIV to HIV-1 CTLs.
evade the immune system (Nabel, 2001).
Multiple possible mechanisms for the failure of CTLs Results
to prevent the development of AIDS have been pro-
posed. Mutation of HIV-1 sequences that encode key To explore the hypothesis that HIV-1 encodes factors
CTL epitopes leads to escape from CTL recognition that protect infected primary T cells from CTLs, a flow
(Barouch et al., 2002; Borrow et al., 1997; Goulder et al., cytometric technique was utilized to detect killing (Col-
1997; Phillips et al., 1991). In addition, anti-HIV-1 CD4 lins et al., 1998). This approach quantifies the percent-
age of cells that are infected by detecting the expression
of a marker gene (PLAP) and uses light scatter to dis-*Correspondence: klcollin@umich.edu
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Figure 1. HIV-1 Molecular Clones
(A) Schematic diagram of HXB-PI (Chen et
al., 1996). Hatched boxes indicate genes that
are not expressed.
(B) Schematic diagram of NL-PI (Collins et al.,
1998). This construct was derived from the
molecular clone NL4-3 and contains open
reading frames for all accessory proteins.
(C) Schematic diagram of NL-PI-5HXB.
(D) Schematic diagram of NL-PI-3HXB.
(E) Schematic diagram of NL-PI revHXB. The
only difference between the genomes shown
in (B) and (E) is a point mutation that changes
the amino acid at position 60 from phenylala-
nine to leucine (see also Figure 3A). In all other
parts, the filled-in open reading frames were
derived from the HXB-PI molecular clone. The
arrow indicates the approximate location of a
frame shift mutation disrupting nef. All NL4-3
derivatives were modified to express the Gag
epitope SL9 as previously described (Collins
et al., 1998), and all NL4-3 derivatives shown
here express the accessory genes (vpr and
vpu).
criminate alive cells from dead cells (Collins et al., 1998). (Figures 2A–2C). In agreement with prior reports, our
data indicated that up to 6-fold more NL-PI-infectedSpecific killing of infected cells can be measured as a
decline in the percentage of alive, PLAP cells. In a cells survived anti-Gag CTL killing than HXB-PI-infected
cells. The difference in susceptibility to CTL lysis wasprevious study, this methodology allowed the determi-
nation that HIV-1 Nef protects infected cells from CTL most apparent in the absence of Nef expression (e.g.,
Figure 2A shows that the addition of CTLs dropped thekilling by downmodulating MHC-I (Collins et al., 1998).
To determine whether other HIV factors might protect rate of alive, HXB-PI infected cells from 18% to 2%
[11% survival], whereas it only dropped the rate of NL-infected primary T cells from CTLs, we asked whether
cells infected with different HIV-1 genomes varied in PI infection from 20% to 10% [50% survival]). The pres-
ence of Nef increased survival of cells infected with boththeir sensitivity to CTL recognition and lysis. The ratio-
nale for this approach is that HIV is variable in its geno- viruses (Figures 2B and 2C). However, expression of Nef
and the NL-PI factor resulted in optimal cell survivalmic sequence due to the error-prone nature of reverse
transcriptase. The host immune system exerts selective (68% survival with Nef plus the NL-PI factor compared
with 50% for Nef plus HXB-PI, Figures 2B and 2C).pressure, causing active forms of viral genes important
for immune evasion to be selected (Carl et al., 2001; To map the genetic element in NL-PI responsible for
protection from CTL killing, we constructed a chimericMunch et al., 2001). Conversely, in the absence of im-
mune selective pressure from the host (e.g., with growth viral genome in which the 5 region of HXB-PI was sub-
stituted into NL-PI (NL-PI-5HXB, Figure 1C). We foundin vitro or in patients with AIDS), active forms of protec-
tive genes can be lost (Carl et al., 2001; Chen et al., that this substitution did not affect CTL killing (Figure
2D). Thus, a gene in the 3 portion of the NL-PI genome1996; Collins and Baltimore, 1999; Collins et al., 1998).
One well-studied example of differential recognition of was probably responsible for the observed resistance
to CTL killing. To confirm this, we substituted the 3cells infected with different HIVs is that cells infected
with HIV molecular clone HXB-PI (Chen et al., 1996; region of HXB-PI into the 3 region of NL-PI (NL-PI-
3HXB, Figure 1D). As expected, this substitution ren-Collins et al., 1998) are more susceptible to lysis by
CTLs than cells infected with another cloned HIV-1 (NL- dered cells susceptible to CTL killing (Figure 2E). Thus,
the gene of interest is located in a 3 kb region in the 3PI). The explanation for differential CTL recognition of
cells infected with these two viruses was not known, end of NL-PI.
The 3 portion of the genome contains tat, rev, env,except that it was not due to expression of Vpu and
Vpr by NL-PI (Collins and Baltimore, 1999) (Figures 1A vpu, and vpr open reading frames. Because vpr and vpu
had already been eliminated as candidates (Collins andand 1B).
As a first step to understand why HXB-PI-infected Baltimore, 1999), we focused on tat, rev, and env. A
sequence comparison failed to reveal a difference in thecells were more sensitive to CTLs, we used the flow
cytometric CTL killing assay to confirm the basic result NL-PI and HXB-PI tat genes. However, NL-PI contained
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Figure 2. CTL Killing Assays of Primary T Cells Infected with Different HIV-1 Molecular Clones
(A and B) Flow cytometric measurement of anti-HIV-1 CTL-mediated killing of primary T cells infected with NL-PI versus HXB-PI. PBMCs
infected with the indicated molecular clone were mock-treated (panels 1 and 2) or treated with anti-Gag SL9 CTL clone 161JXA14 at an
effector:target ratio of 10:1 (panels 3 and 4), stained, and analyzed by flow cytometry as described previously (Collins et al., 1998). Only alive,
CD8 cells were gated. Uninfected control cells were all PLAP and fell to the left of the vertical line. The percentage of infected (PLAP
cells) is indicated in each plot and was used to generate the survival curves shown in (C) and (D). (A) Molecular clones in which the nef open
reading frame was disrupted. (B) Molecular clones in which the nef sequence was intact. Results shown are typical of more than three
independent experiments.
(C) Graphical representation of data from flow cytometric CTL killing assay shown in (A) and (B). The negative control (“mis-matched epitope”)
is a virus with two amino acid substitutions in the SL9 epitope.
(D) The 5 portion of HXB-PI does not confer susceptibility to CTL killing. PBMCs were infected with either NL-PI parent virus (negative control
that has a mis-matched epitope), NL-PInef, NL-PI-5HXB, or HXB-PInef and treated with CTLs. Killing was assayed as previously described
(Collins et al., 1998).
(E) The 3 region of NL-PI confers resistance to CTL killing. PBMCs were infected with the indicated viral clones: NL-PI parent virus (negative
control that has a mis-matched epitope), NL-PInef, NL-PI-3HXB, or HXB-PInef, and assayed for sensitivity to CTL killing as described
previously (Collins et al., 1998). Results shown for (C) through (E) are typical of more than three independent experiments.
a single amino acid difference in the second exon of rev responsible for the increased resistance of cells infected
with NL-PI, we changed this amino acid back to leucine(Figure 3A) and a number of amino acid differences in
env. The single amino acid change in the second exon (NL-PIrevHXB, Figures 1E and 3A). We then asked whether
molecular clones that were identical except at this posi-of NL-PI rev (L60F) is a naturally occurring variant at
this position, but was introduced during the construction tion would differ in sensitivity to CTL recognition. Indeed,
the leucine substitution resulted in improved CTL recog-of the molecular clone, when a fragment from HXB-PI
was ligated into NL4-3 to generate the fully infectious nition and lysis (Figure 3B). This change also increased
the initial burst of virus production from infected primarymolecular clone, NL-PI (Collins et al., 1998).
To demonstrate that the mutation at position 60 was T cells by a small amount (approximately 50%) in the
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Figure 3. Rev-Mediated Resistance to CTL Killing Can Be Overcome by High Epitope Density
(A) Comparison of amino acids 23 to 84 of rev sequences from various HIV-1 molecular clones. (Exon 2 contains amino acid residues 27 to
116.) The mutation in NL-PI (L60F) is denoted by the arrow. A mutation at this position is also found in the infectious primary isolate, 94UG114.
Modified from Pollard and Malim (1998).
(B) Reversion of rev sequence confers sensitivity to CTL killing. Flow cytometric killing assay of PBMCs treated with anti-Gag CTL clone
161JXA14. PBMCs were infected with either NL-PInef, NL-PInef, or NL-PInef revHXB (mutation at position 60 in NL-PI reverted from a
phenylalanine to a leucine), and treated with CTLs.
(C) Exogenously added peptide (SL9) rescues killing of primary T cells infected with NL-PInef. The indicated infected cells were pulsed with
peptide antigen and incubated with anti-Gag CTL clone 161JXA14 as previously described (Collins et al., 1998). HLA-A2-negative cells that
do not bind the peptide were used as a negative control.
first 1 to 2 days, but did not significantly affect viral nize p24, p17, and their precursors. We found that there
was a 2- to 3-fold reduction in total Gag protein levelsspread over a 10 day period (see Supplemental Figure
S1A at http://www.immunity.com/cgi/content/full/18/2/ resulting from expression of Rev L60F in transfected
293 cells (Figures 4A and 4C) and infected, primary T289/DC1).
Rev is required for the expression of Gag, Pol, and cells (Figures 4B and 4D).
There was a smaller effect of the Rev mutation on EnvEnv proteins because it facilitates transport of unspliced
(gag/pol) and singly spliced (env) messenger RNAs protein levels at the 48 hr time point that we examined
(Figure 4A). This relatively small effect is not surprising(mRNAs) from the nucleus to the cytoplasm. Thus, it is
possible that the rev mutation reduces CTL killing by because the Rev protein functions by counteracting the
normal tendency of intron-containing transcripts to re-limiting Gag protein expression and Gag epitope density
on the surface of infected cells. To test this hypothesis, main in the nucleus. Because there are fewer introns in
the env transcript than in the gag/pol transcript, a lowerwe incubated infected cells with exogenously added
peptide epitope (Gag SL9) and assayed for sensitivity level of rev activity may suffice to allow transport of env
mRNA to the cytoplasm. Consistent with this, anotherto CTL killing as previously described (Collins et al.,
1998). Indeed, we found that the addition of exogenous group has demonstrated that env RNA is detectable in
the cytoplasm at earlier time points than gag/pol RNA,peptide allowed NL-PInef to be recognized as well as
HXB-PInef (Figure 3C). These data indicate that the implying that higher amounts of Rev protein must be
synthesized to achieve transport of transcripts harbor-CTLs can kill the infected cells expressing the mutant
Rev when there is high epitope density; however, they ing a greater number of introns (Pomerantz et al., 1990).
In addition to limiting late gene expression, an attenu-do not prove that the only effect of Rev is to limit antigen
presentation. ated rev allele should result in either no change or even
an increase in expression of fully-spliced, early geneTo confirm that Gag protein levels were altered by
this rev mutation, a Western blot analysis of p24 and transcripts. Conveniently, in the HIV-1 genomic con-
structs used in these assays, PLAP is encoded as a fullyp17 Gag from transfected 293 cells or infected primary
T cells was performed. The Gag protein is synthesized as spliced transcript under the control of the Nef regulatory
elements (Figure 1; Chen et al., 1996; Collins et al., 1998).a 55 kDa precursor and is processed to lower molecular
weight forms (p24, p17, p6, and p7) by the viral protease. Thus, PLAP mean fluorescence as measured by flow
cytometry serves as a surrogate marker for early, rev-The antibodies used for this Western blot analysis recog-
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Figure 4. The Effect of Different rev Alleles
on HIV Protein Expression
(A–E) Gag but not PLAP protein expression
is reduced in cells expressing NL-PI. 293 cells
were transfected with the indicated construct
(A and C) or primary T cells were infected with
the indicated virus (B, D, and E). Cell lysates
normalized first for total protein and then ad-
justed for any differences in transfection/
infection efficiency were assayed by immu-
noblot to compare viral protein expression (A
and B). Immunoblots from four transfections
(C) or three infections (D) were quantified by
densitometry, summing the pixel density of
each Gag protein band, and normalizing to
Gag expression by HXB-PI. The mean /
SEM is shown. Early gene (PLAP) expression
in infected primary T cells was measured flow
cytometrically (E). The mean fluorescence in-
tensity measured in four independent experi-
ments is reported relative to that of cells in-
fected with HXB-PI. The mean / SEM is
shown.
(F–H) Gag but not Nef protein expression is
reduced in a primary viral isolate from an
asymptomatic person. 293 cells were trans-
fected with the indicated construct and cell
lysates were prepared as described above,
except that immunoblots were probed with
antibodies directed against Gag or Nef (F).
Immunoblots from three independent experi-
ments were quantified by densitometry, and
the mean expression / SEM relative to
YU-2 is shown (G and H).
independent, gene expression. Indeed, a flow cytomet- modulation. As we have shown here, the combined ef-
fect of Rev L60F and Nef expression significantly re-ric assessment of PLAP expression revealed that NL-
PI-infected primary T cells expressed somewhat more duced CTL recognition (Figures 2B and 2C).
To determine whether Gag levels vary among unmodi-PLAP than NL-PI revHXB-infected primary T cells (Figure
4E). These data suggest that attenuated rev alleles fied HIV-1 genomes, we examined the replication com-
petent molecular clones YU-2 (Li et al., 1991) andwould provide two measures of protection from CTLs.
They diminish late gene product levels so that there is 94UG114 (Gao et al., 1998). YU-2 was isolated from an
immune privileged site (the brain) of an AIDS patient andless viral protein available to serve as antigen, and they
maintain high expression of fully spliced transcripts, so would be expected to have experienced very little
immune selective pressure. 94UG114 was isolated fromsuch as those encoding Nef, to promote MHC-I down-
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Figure 5. Rev Activity from Natural HIV Isolates Varies and Determines the Sensitivity of HIV-Infected Cells to Anti-Gag CTL Killing
(A) Intracellular Gag expression is reduced in T cells infected with chimeras containing rev alleles from asymptomatic individuals (94UG114,
90CF056, and 92NG003) compared with rev alleles from those with AIDS (84ZR085, 92NG083, and YU-2). CEM-NKR-CCR5 T cells (Trkola et
al., 1999) were infected with the indicated chimera, harvested after 48 hr, and stained for intracellular Gag as previously described (Collins
and Baltimore, 1999). The results are summarized from four separate experiments, normalized to an internal control (HXB-PI infected cells).
The mean / SD is shown.
(B) Primary T cells infected with NL-PI are resistant to CTL killing. Flow cytometric CTL killing assay of primary T cells (target cells) treated
with anti-Gag SL9 CTL clone 161JXA14 (effector cells) at a 1:2.5 target:effector ratio in triplicate as described previously (Collins et al., 1998).
The mean percent survival / SD is shown. These results are typical of two independent experiments.
(C) Early gene (PLAP) expression does not correlate with disease stage. CEM-NKR-CCR5 T cells (Trkola et al., 1999) were infected with the
indicated chimera, harvested after 48 hr, and stained for PLAP. The results are summarized from four separate experiments, normalized to
an internal control (HXB-PI infected cells). The mean / SD is shown.
(D) Comparison of primary isolate rev alleles to YU-2 rev.
the blood of an asymptomatic individual and so would However, our interpretation of this experiment was
complicated by the fact that there was less high molecu-be expected to have experienced selection by an effec-
tive anti-HIV immune response. A comparison of their lar weight Gag protein in 94UG114 transfected cells,
and we also noted that YU-2 and 94UG114 differed inrev sequences revealed a remarkable amount of se-
quence variability near amino acid 60 (Figure 3A). In- p17 expression more than in p24 expression (Figure 4F).
This may be due to differential processing, antibodydeed, like at least eighteen rev alleles in Genbank,
94UG114 had an isoleucine instead of a leucine residue recognition, or stability of these proteins. To avoid these
complications, we made chimeric viruses composed ofat position 60. The viruses were both infectious and
produced similar amounts of virions when transfected NL-PI and a panel of cloned primary isolate genomes
(Gao et al., 1998; Li et al., 1991). In these chimeras, onlyinto 293 cells (see Supplemental Figure 1B at http://
www.immunity.com/cgi/content/full/18/2/289/DC1). the shaded region encompassing the rev exons shown
in Figure 1D was derived from the primary isolate. TheTo determine whether they differed in viral protein ex-
pression levels, we performed a Western blot on lysates remainder of the virus (including the entire gag ORF)
was derived from NL-PI. To assess Rev function, PBMCsfrom 293 cells transfected with their genomes. We found
that there was less total Gag protein and no significant and CEM T cells were infected with the chimeric viruses
as described in Experimental Procedures. Forty-eightdifference in Nef protein expression from 94UG114 com-
pared with YU-2 (Figures 4F–4H). hours later, intracellular p24 Gag and PLAP expression
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Figure 6. Rev Attenuation Specifically De-
creases Recognition of Late Gene Product
Epitopes
(A) Rev activity of HIV molecular clones. A
Northern blot of 20 g of cytoplasmic RNA
from 293 T cells transfected with the indi-
cated molecular clone was probed using a
DNA sequence common to all splice products
(the nef ORF). Splice products were quanti-
fied using a phosphorimager and the mean
ratio of unspliced:multiply spliced / SD is
shown.
(B) HXB-PI rev subgenomic fragment has a
greater ability to restore Rev activity in trans
than NL-PI rev. 293 cells were transfected
with Mrev alone, or with the indicated rev
allele, and were stained for intracellular Gag
expression as described in Experimental Pro-
cedures. There was no significant Gag protein
expression by Mrev or the rev allele con-
structs alone (data not shown). Data are com-
piled from three independent experiments.
The mean / SD is shown.
(C) Anti-HIV CTLs against Gag, Tat, and Env
protein antigens have similar activity against
peptide pulsed targets. Peptide pulsed
BLCLs were incubated with CTLs for 4 hr at
the indicated effector:target ratio, and per-
cent specific lysis was measured. The aster-
isk indicates killing of chromium-loaded tar-
gets that were not pulsed with peptide.
(D) Anti-HIV CTL clones against Gag, Tat, and
Env peptide antigens differentially recognize
HIV-infected target cells. Primary T cells ex-
pressing HLA-A2, HLA-B7, or HLA-B53 were
infected with the indicated HIV and treated
with anti-Gag SL9, anti-Env IL9 (IPRR
IRQGL), or anti-Tat EW10 (EPVDPRLEPW),
respectively, at an effector:target ratio of 5:1.
Infection rates were 13%–16% for Gag CTL
killing assay, 7.4%–20% for Env CTL killing
assay, and 3%–3.6% for Tat CTL killing
assay. For the Env CTL killing assay, the
higher infection rate was for the cells infected
with NL-PIrevHXB. The asterisk indicates sur-
vival of cells infected with viruses that have
two amino acid substitutions in the recog-
nized peptide antigen.
were measured flow cytometrically. We found that intra- observed (Figures 5B and 5C). However, to be certain
that Rev was responsible, we directly measured Revcellular Gag expression levels from the chimeric viruses
varied over a 3-fold range (Figure 5A) and correlated activity of the chimeric viruses with the greatest differ-
ences in Gag expression levels (YU-2 and 92NG003). Toinversely with resistance to CTL killing (Figure 5B). Strik-
ingly, cells infected with isolates derived from asymp- accomplish this, cytoplasmic RNA was harvested from
293 T cells transfected with a subset of the moleculartomatic individuals (90CF056, 94UG114, and 92NG003)
expressed less Gag (p  0.05) and were more resistant clones and Northern blots were performed using a probe
common to all transcripts (the nef ORF). Results fromto CTLs (p  0.05). In contrast, there was no correlation
between early gene (PLAP) expression and disease these experiments revealed significant differences in the
ratio of unspliced:fully spliced RNA for YU-2 comparedstage or CTL killing (Figure 5C).
There are other genes contained within the segment with 92NG003 (Figure 6A). These data confirmed that
Rev activity from the AIDS isolate was greater than thatof the genome cloned from the primary isolates (vpu,
vpr, env, and tat). However, these other gene products from the asymptomatic person, and this difference in
activity accounts for the observed changes in Gag levelsare not likely to specifically affect Gag levels and CTL
killing. Changes in Tat or Vpr activity might affect HIV and sensitivity to anti-Gag CTLs. As a control, we also
examined the Rev activity of HXB-PI, NL-PI, and NL-gene expression but would be expected to affect ex-
pression of PLAP and Gag similarly (Emerman and PIrevHXB. As expected, we found that Rev activity was
reduced by the point mutation found in NL-PI (Figure 6A).Malim, 1998; Felzien et al., 1998). In contrast, alterations
in Rev activity would be expected to change Gag levels To rule out the possibility that differences in Gag ex-
pression by these viruses resulted from cis effects ofindependently of early gene (PLAP) expression, as we
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the mutation on regulatory regions of the viral genome, bly improved survival of cells that also expressed Nef.
Thus, the combined effects of Nef and Rev determinedrather than by altering Rev protein function, we asked
the sensitivity of infected cells to CTL killing.whether the mutant Rev protein would behave similarly
The data presented here suggest that, in vivo, the revwhen supplied in trans. This was tested by cotransfect-
gene sequence may be a target of immune selectiveing the indicated rev allele with an HIV genome that
pressure and that infected cells harboring attenuatedlacked a functional rev allele (Sadaie et al., 1988). As
alleles have a survival advantage in the face of a strongshown in Figure 6B, Rev activity supplied by HXB-PI
CTL response against viral late genes. Indeed, we foundRev was significantly greater than that supplied by NL-
variations in Gag protein expression levels from a panelPI, confirming the fact that differences in Gag expression
of HIV-1 chimeras isolated from patients with normalresulted from differences in Rev protein function, rather
disease progression who were at different diseasethan from an affect on cis-acting regulatory elements.
stages. Patients at an asymptomatic stage with an intactAll of the above experiments demonstrating that Rev
immune response seemed to select viruses that wereconfers resistance to CTL killing were performed using
resistant to CTLs. On the other hand, we found that cellsa CTL clone directed against the Gag SL9 epitope pre-
infected with viruses isolated from people with AIDSsented by HLA-A2. To determine whether our results
were more sensitive to CTLs, presumably because anwere generalizable to other CTLs and to confirm that
immune system destroyed by AIDS is unable to exertthe protective effect of Rev was limited to CTLs directed
much selective pressure. Interestingly, we found thatagainst late gene products, we tested CTL clones di-
the highest Gag expression level was achieved by therected at another late gene product presented by HLA-
YU-2 chimera. YU-2 was originally isolated from an im-B7 (Env peptide antigen, IL9 [IPRRIRQGL]) and an early
mune privileged site (the central nervous system) of agene product presented by HLA B53 (Tat peptide anti-
person with AIDS and would therefore have experiencedgen, EW10 [EPVDPRLEPW] [Addo et al., 2001]). All the
the least selective pressure from the immune system.CTL clones had similar activity against peptide-pulsed
The data presented here are analogous to recent find-BLCL target cells (Figure 6C). Interestingly, however,
ings that asymptomatic SIV-infected monkeys have nefthey differed in their capacity to lyse HIV-infected
alleles that downmodulate MHC-I more efficiently thanprimary T cells. Most notably, the anti-Gag and Env
monkeys with AIDS (Carl et al., 2001).CTLs were much more active than the anti-Tat CTLs
The differences we observed in Gag expression level(Figure 6D).
and sensitivity to CTLs resulted from differences in RevIn addition, we found that cells infected with the less
function, because they were caused by a region of theactive Rev allele (NL-PInef) survived treatment with
HIV-1 genome encompassing the rev exons and notanti-Env IL9 CTLs approximately 1.7-fold better than
by sequence variations in the LTRs or in Gag itself.cells infected with the more active rev allele (Figure
Moreover, the pattern of gene expression changes was6D). The smaller effect of the rev allele on Env peptide
consistent with a Rev-effect, in that it affected early andrecognition (1.7-fold for Env versus 5-fold for Gag, [Fig-
late gene products differently. Finally, a direct measure-ure 6D]) is consistent with its smaller effect on Env pro-
ment of nucleocytoplasmic transport efficiency sup-tein expression (Figure 4A).
ported a role for Rev. Taken together, the results pre-As predicted, CTLs directed against Tat epitopes had
sented here strongly support the hypothesis thata pattern of activity that was opposite to that observed
variations in Rev activity can alter sensitivity of HIV-for CTLs directed against late gene product epitopes.
infected cells to anti-Gag CTL killing. Importantly, theThe anti-Tat EW10 CTLs specifically lysed about 12%
data also suggest that less active rev alleles may beof cells infected with the attenuated Rev (NL-PInef)
specifically selected by an active immune response andand 4% of cells infected with the active rev allele (HXB-
may assist with HIV immune evasion.PInef). Although these numbers were low (probably
It was somewhat surprising to learn that relatively
because the expression level of Tat is very low), the
small changes in protein expression that did not have
pattern is consistent with our model that the attenuated
dramatic effects on virus production affected CTL rec-
Rev L60F affects early and late gene products in a pat- ognition. One might think that this indicates any attenu-
tern that mirrors its affects on gene expression. These ated virus with diminished protein expression would
data argue against a global effect of Rev on antigen have a survival advantage in the presence of CTLs. How-
presentation. ever, it is important to note that only a Rev effect would
accomplish this without also reducing Nef levels and
Discussion the protective effect of MHC-I downmodulation.
Attenuation of Rev might be detrimental if it substan-
In this study, we examined the effects of viral factors tially reduced virion production and if it caused an in-
on the ability of various anti-HIV CTL clones to recognize crease in early gene expression sufficient to increase
infected cells. We confirmed a role for Nef and also sensitivity of infected cells to CTLs directed against early
discovered that another factor, Rev, affected CTL recog- gene epitopes. Our data suggest that in a particular
nition. Specifically, we found that an attenuated rev al- person, the optimal level of Rev activity would depend
lele can protect infected cells from CTL killing by down- on which CTLs were dominant and how active the im-
modulating late gene product expression. Late gene mune response was. Of note, our studies indicate that
products are highly expressed structural proteins that upregulation of early genes would not necessarily result
are a rich source of antigenic peptides for CTL recogni- from Rev attenuation, as we did not observe a significant
tion. The effect of Rev on CTL recognition was most increase in early gene expression in the chimeric primary
isolates harboring the less active natural rev alleles.apparent in cells that lacked Nef; however, it reproduci-
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Infection of Primary T CellsMoreover, the anti-Tat CTLs examined here were not
Virus was prepared from HIV-1 molecular clones and used to infectvery active against HIV-infected targets, probably be-
T cells as previously described except that some primary isolatecause Tat protein is not expressed to very high levels
chimeric viruses (92NG003, 84ZR085, 92NG083, 90CF056, and YU-2)
in HIV-infected cells. Finally, early gene upregulation were pseudotyped with pCDNA gp160 (Invitrogen, Carlsbad, Califor-
might be beneficial if increased Nef expression (another nia) to increase infectivity (Chen et al., 1996; Collins et al., 1998).
early gene product) further downmodulated MHC-I. Ad-
ditional studies are now needed to determine whether CTL Assay
The anti-HIV-1 Gag CTL clone 161JXA14 (Collins et al., 1998) wasRev activity in an individual person changes with disease
the generous gift of Spiros Kalams from Harvard Medical School.progression.
The other CTLs (anti-Env IL9 and anti-Tat EW10 CTLs) were isolatedInterestingly, it has been previously reported that at-
as described (Addo et al., 2001; Collins et al., 1998). All CTLs weretenuated rev alleles occur naturally and persist in in-
propagated and assayed by chromium release as previously de-
fected people—although the reason for why this might scribed (Collins et al., 1998; Yang et al., 1996). Flow cytometric CTL
occur was not clear (Hua et al., 1996; Iversen et al., assays were performed as previously described (Collins et al., 1998).
1995). Moreover, there are reports that HIV-1-infected In brief, 2 days postinfection, infected target cells (100,000) were
mixed with anti-HIV-1 Gag CTL clones at the indicated effector:tar-cells from asymptomatic versus symptomatic individu-
get ratio for 4 hr at 37C and 5% CO2. Target cells were total (infectedals have relatively low levels of unspliced (Rev-depen-
plus uninfected) primary T cells. Infection rates varied from 3%–dent) transcripts (Furtado et al., 1995; Michael et al.,
30%, but were similar (within 10%) for each experiment. To assess
1995), although the mechanism for the change in splic- killing, alive infected cells were quantified flow cytometrically, by
ing patterns was not elucidated. In addition, there is one staining for PLAP expression (identifies the infected cells) and CD8
report that Rev protein sequences tend to increase in (excludes the CTLs from the analysis). Cells were also stained with
an antibody to MHC-I HLA-A2 to assess MHC-I downmodulation.complexity with disease progression (Martins et al.,
The following primary antibodies were used: polyclonal rabbit anti-1991), although the reason for this was not known. The
PLAP (DAKO, Carpinteria, California; 1:500); biotinylated mono-data presented here provide a conceptual framework
clonal murine anti-A2 (One Lambda, Canuga Park, California, 1:40);for these results, providing an explanation for why atten-
and monoclonal murine anti-human CD8 conjugated with Cy-
uation of Rev might have a selective advantage in Chrome (Pharmingen, Franklin Lakes, New Jersey; 1:20). The cells
asymptomatic people. were then washed and stained with the following secondary antibod-
ies: goat anti-rabbit IgG conjugated with fluorescein isothyiocyanate
Experimental Procedures (FITC, Biosource International, Camarillo, California, 1:250) and
Streptavidin conjugated to Phycoerythrin (PE, Leinco Technologies,
DNA Constructs St. Louis, Missouri, 1:250). Cells were washed and fixed overnight
The construction of HXB-PI, HXB-PInef, NL-PI, and NL-PInef ex- at 4C in 2% paraformaldehyde.
pressing the Gag SL9 epitope has been described previously (Collins Samples were analyzed by flow cytometry on a Becton Dickinson
et al., 1998). NL-PI-5HXB was constructed by exchanging the SpeI- FacScan flow cytometer (San Jose, California) and the results ana-
SalI fragment of NL-PI nef for the same fragment in HXB-PI. NL- lyzed using Cell Quest software. Data from 10,000 CD8 virus-
PI-3HXB was constructed by exchanging the SalI-NotI fragment in infected cells exhibiting appropriate light-scattering characteristics
NL-PInef for the same fragment in HXB-PI. NL-PInef revHXB was were collected. Dead cells and CD8 cells were excluded by for-
constructed by first cloning the SalI-NotI fragment of NL-PI into ward/side scatter properties and Cy-chrome staining, respectively.
pBluescript. Then, the point mutation was reverted by a standard The percentage of alive PLAP cells was used to calculate percent
PCR mutagenesis protocol (Higuchi, 1990) and was sequenced to survival as follows: [(% PLAP in plus CTL sample)/(the average %
confirm that only the intended change had been made. The mutated PLAP of two duplicate control samples)](100). The data obtained
SalI-NotI fragment was subcloned back into NL-PInef. We obtained from this approach was highly reproducible, and duplicates within
pYU.2, p94.UG114.1.6, p84ZR085.1, p92NG083.2, p90CF056, and a given assay typically did not vary by more than 5%–10% (see
p92NG003.1 from the NIH AIDS Research and Reference Reagent Figures 6C and 6D for comparison between chromium release and
Repository, Division of AIDS, NIAID, NIH, from Dr. Beatrice Hahn flow cytometric CTL assays).
(Gao et al., 1998; Li et al., 1991). We constructed chimeric viruses
by amplifying a 3 kb region from primary isolate genomes using
Western Blot Analysis of HIV-1 Gag and Env ProteinsPCR with the following oligonucleotides: The 5 primer used for all
293 cells were cotransfected by a standard calcium phosphatemolecular clones was: 5-CAGAATTGGGTGTCGACATAGCAG-3;
method with or without a GFP expression vector (pMSCV-GFP) andthe 3 primer for 94UG114.1.6 was: 5-AGTGCGGCCGCGCCACCCA
various individual HIV-1 molecular clones (HXB-PInef, NL-PInef,TCTTATAGTAAAGCCCTTTCCAAGCCCTG-3; the 3 primer for
NL-PInefrevHXB, pYU.2, p94.UG114.1.6). Primary T cells were in-84ZR085.1 was: 5-AGTGCGGCCGCGCCACGCATCTTATAGCAAA
fected as described previously (Collins et al., 1998). Flow cytometryGCCCTTTCTAAACCCTG-3; the 3 primer for YU-2, 92NG003.1,
was used to determine the percentage of cells infected or trans-92NG083.2 was: 3-AGTGCGGCCGCGCCACCCATCTTATAGCAAAG
fected by expression of PLAP or GFP. The remainder of the cellsCTCTTTCCAAGCCCTG-5; the 3 primer for 90CF056 was: 53AGT
were lysed for 30 min on ice in 40 l of lysis buffer (50 mM Tris [pHGCGGCCGCGCCACCCATCTTATAGCAAGCTTCTTTCAAAGCC
7.3], 5 mM MgCl2 , 1% NP-40, and 1 mM PMSF). Lysates wereCTG-5. We digested the resulting products with SalI and NotI and
centrifuged at 12,000  g for 30 min at 4C to remove debris. Sam-cloned them into NL-PInef digested with the same enzymes.
ples were normalized for protein concentration and transfection/PMrev was obtained Dr. Dr. Reza Sadaie via the AIDS Research
infection efficiency. Transfection efficiency was determined as theReference Reagent Program, Division of AIDS, NIAID, NIH. In brief,
percentage of cells positive for GFP or PLAP. (GFP was used forsite-directed mutagenesis was used to introduce a termination co-
unmodified YU-2 and 94UG114.1.6 genome transfections whereasdon (TGA) in place of the glycine residue 6 (GGA) in the rev gene
PLAP was used for PLAP-expressing HIV-1s.) Lysates were thenand a leucine (CTG) codon in place of arginine (CGG) at residue 52
separated on 4%–15% polyacrylamide gradient gels and elec-of the tat reading frame of pHXB2gpt, an infectious proviral clone of
troblotted to Immobilon (Millipore, Bedford, Massachusetts). Mem-IIIB. The resulting mutant is unable to synthesize Rev, but expresses
branes were blocked in 5% nonfat dry milk in TBST (10 mM Trisfunctionally intact, active Tat. Cotransfection of the pMrev with a
[pH 8.0], 140 mM NaCl, and 0.5% Tween-20) for 1 hr at room temper-rev cDNA clone restores the normal transcription pattern (Sadaie
ature. To detect HIV-1 proteins, blots were incubated with the follow-et al., 1988). To compliment the Rev mutation in mRev with NL-PI
ing reagents obtained through the AIDS Research Reference Re-and HXB-PI rev alleles, the NotI-SalI subgenomic fragments con-
agent Program, Division of AIDS, NIAID, NIH; antiserum to HIV-1taining the rev exons (but not any Gag sequences) were inserted
into PmeI site of expression plasmid pEBB. p17 (1:1250) was from Dr. Paul Spearman, HIV-1sf2 p24 antiserum
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(1:50,000) and antiserum to HIV-1 gp120 (1:10,000) from Dr. Michael References
Phelan. When staining was performed for both Gag and Env simulta-
neously, blots were washed and incubated first with goat anti-rabbit Addo, M.M., Altfeld, M., Rosenberg, E.S., Eldridge, R.L., Philips,
IgG conjugated with horseradish peroxidase (HRP, Jackson Immuno M.N., Habeeb, K., Khatri, A., Brander, C., Robbins, G.K., Mazzara,
Research Laboratories, West Grove, Pennsylvania, 1:100,000) and G.P., et al. (2001). The HIV-1 regulatory proteins Tat and Rev are
then, after washing, with rabbit anti-sheep IgG conjugated with HRP frequently targeted by cytotoxic T lymphocytes derived from HIV-
(Dako, Carpinteria, California, 1:20,000). The proteins of interest 1-infected individuals. Proc. Natl. Acad. Sci. USA 98, 1781–1786.
were visualized using enhanced chemiluminescence (ECL) ac- Appay, V., Nixon, D.F., Donahoe, S.M., Gillespie, G.M., Dong, T.,
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